WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsHyperfine Inc (HYPR)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 128496% more annual revenue ($21.27B vs $16.54M). GEHC leads profitability with a 9.3% profit margin vs -210.7%. GEHC earns a higher WallStSmart Score of 65/100 (C+).

GEHC

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

HYPR

Avoid

30

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: -7.66

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC1 strengths · Avg: 8.0/10
P/E RatioValuation
16.3x8/10

Attractively priced relative to earnings

HYPR2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
44.8%10/10

Revenue surging 44.8% year-over-year

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.774/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-617.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

HYPR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$73.43M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-101.2%2/10

ROE of -101.2% — below average capital efficiency

Free Cash FlowQuality
$-7.30M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio.

Bull Case : HYPR

The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 44.8% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, Free Cash Flow.

Bear Case : HYPR

The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

GEHC profiles as a value stock while HYPR is a hypergrowth play — different risk/reward profiles.

HYPR carries more volatility with a beta of 1.50 — expect wider price swings.

HYPR is growing revenue faster at 44.8% — sustainability is the question.

HYPR generates stronger free cash flow (-7M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (65/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Hyperfine Inc

HEALTHCARE · MEDICAL DEVICES · USA

Hyperfine Inc. is a pioneering force in medical technology, renowned for developing the world’s first FDA-cleared portable MRI system, which significantly enhances diagnostic imaging accessibility at the point of care. By combining innovation with cost-efficiency, the company improves patient outcomes and facilitates rapid clinical decision-making. As healthcare continues to evolve, Hyperfine is strategically positioned to capture growth opportunities within the expanding imaging diagnostics market, presenting a compelling investment prospect for institutional investors focused on transformative healthcare solutions.

Visit Website →

Want to dig deeper into these stocks?